NEW YORK (GenomeWeb) – Horizon Discovery has formed a strategic partnership with Axol Bioscience to develop and commercialize genomically modified and differentiated induced pluripotent stem cells (iPSCs) for neuronal and cardiovascular research, the companies announced today. 

"This partnership builds on Axol’s strong position in the use of stem cell technology, and the combination of Horizon's gene editing expertise with Axol's experience in working with iPSCs will offer valuable new tools for researchers," Axol Chief Business Officer Sanj Kumar said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.